Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Metastatic Breast Cancer Clinical Trial

Official title:

Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05176080
• Other study ID #: BC-IIT-FMTN-SHR6390-ET
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: December 8, 2021
• Est. completion date: January 30, 2026

Study information

• Verified date: April 2023
• Source: Henan Cancer Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer.

Description:

This study would enroll patients with hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer, aimed to evaluate the efficacy and safety of treatment with famitinib combined with SHR6390 and endocrine therapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 65
• Est. completion date: January 30, 2026
• Est. primary completion date: May 30, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Local recurrent or metastatic breast cancer unsuitable for chemotherapy, confirmed histologically.
• HR-positive, HER2- negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline).
• Ib: Patients who received no more than 2 line of chemotherapy in advanced setting were recruited; II: Patients who had not received any chemotherapy and no more than 1 line of endocrine therapy.
• 18-75 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status 0~1.
• life expectancy is not less than 12 weeks.
• at least one measurable lesion according to RECIST 1.1.
• Absolute neutrophil count (ANC) = 1.5×10^9/L, Platelets =90×10^9/L, Hemoglobin = 90 g/L; Total bilirubin=1.5 upper limit of normal (ULN);Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)=2.5×ULN (ALT and AST=5×ULN if liver metastasis); blood urea nitrogen (BUN) and Creatinine (Cr)=1.5×ULN
• Left ventricular ejection fraction (LVEF) = 50% and QTc=470 ms

Exclusion Criteria:

• Patients who received Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine kinase inhibitors (TKI); II: Patients who received fulvestrant, everolimus or cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor;
• Ib: Patients who had symptomatic brain metastasis; II: Patients who had brain metastasis;
• Patients unsuitable for endocrine therapy;
• Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption.
• Participated in other drug clinical trials within 4 weeks before admission
• Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
• Active human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
• Has suffered from any heart disease
• Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
• According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).
• Moderate infection occurs within 4 weeks before the first administration (e.g. intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical criteria), fever(> 38.5 ?) of unknown origin occurs during the screening period/before the first administration.
• Researchers believe that patients are unsuitable for any other situation in this study.

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• Famitinib
Famitinib orally, daily or every other day
• SHR6390
SHR6390 orally, daily for 3 weeks followed by 1 week off
• Fulvestrant
Fulvestrant

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	RP2D in phase Ib	Recommended phase II dose (PR2D) in phase Ib	Up to 4 weeks
Primary	ORR in phase II	Objective response rate (ORR) by investigator in phase II	up to 2 years
Secondary	ORR in phase Ib	ORR by investigator in phase Ib	up to 2 years
Secondary	PFS in phase Ib	Progression-Free Survival (PFS) in phase Ib	up to 2 years
Secondary	PFS in phase II	Progression-Free Survival in phase II	up to 2 years
Secondary	AE	The number of patients experiencing any adverse events (AE) during the phase II study time	up to 2 years